Sobi Submits Application for Orfadin to EMA
Sobi's application for Orfadin oral suspension has been validated by EMA.
Sobi announced that the company's application for Orfadin oral suspension has been validated by EMA. This new dosage form has been developed to facilitate the accuracy in administration of the desired Orfadin dose to pediatric patients and to increase expediency for the patients and their caregivers.
The oral suspension is included in a Paediatric Investigation Plan agreed with EMA in March 2012.
Source: Sobi
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
